Exploring the origins of grey matter damage in multiple sclerosis

Nature Reviews Neuroscience

Volumn 16, Issue 3, 2015, Pages 147-158

  Calabrese, Massimiliano ^a   Magliozzi, Roberta ^b,c   Ciccarelli, Olga ^d,e   Geurts, Jeroen J G ^f   Reynolds, Richard ^b   Martin, Roland ^g  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d and University of Bristol   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD BRAIN BARRIER; BRAIN DAMAGE; DEMYELINATING DISEASE; DEMYELINATION; DISEASE PREDISPOSITION; FOLLOW UP; GRAY MATTER; GREY MATTER DAMAGE; HUMAN; INFLAMMATORY INFILTRATE; MENINGITIS; METABOLOMICS; MULTIPLE SCLEROSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PROTEOMICS; RETROGRADE DEGENERATION; REVIEW; VOXEL BASED MORPHOMETRY; WALLERIAN DEGENERATION; WHITE MATTER LESION; ANIMAL; BRAIN CORTEX; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; WHITE MATTER;

ANIMALS; CEREBRAL CORTEX; GRAY MATTER; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; WHITE MATTER;

EID: 84923629275     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn3900     Document Type: Review

References (128)

1. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M. & Weinshenker, B. G. Multiple sclerosis. N. Engl. J. Med. 343, 938-952 (2000).
2. Sospedra, M. & Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol 23, 683-747 (2005).
3. Lill, C. M. et al. CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain 136, 1778-1782 (2013).
4. Ascherio, A. Environmental factors in multiple sclerosis. Expert Rev. Neurother. 13 (Suppl. 12), 3-9 (2013).
5. Dutta, R. & Trapp, B. D. Pathology and definition of multiple sclerosis. Rev. Prat. 56, 1293-1298 (2006).
6. Lassmann, H., Brück, W. & Lucchinetti, C. F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 17, 210-218 (2007).
7. Dawson, J. D. The histology of disseminated sclerosis. Trans. R. Soc. Edin. 50, 517-740 (1916).
8. Brownell, B. & Hughes, J. T. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 25, 315-320 (1962).
9. Chard, D. & Miller, D. Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging. J. Neurol. Sci. 282, 5-11 (2009).
10. Calabrese, M., Filippi, M. & Gallo, P. Cortical lesions in multiple sclerosis. Nature Rev. Neurol. 6, 438-444 (2010).
11. Kidd, D. et al. Cortical lesions in multiple sclerosis. Brain 122, 17-26 (1999).
12. Peterson, J. W., Bö, L., Mörk, S., Chang, A. & Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389-400 (2001).
13. Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D. & Mörk, S. J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 62, 723-732 (2003).
14. Brink, B. P. et al. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J. Neuropathol. Exp. Neurol. 64, 147-155 (2005).
15. van Horssen, J., Brink, B. P., de Vries, H. E., van der Valk, P. & Bø, L. The blood-brain barrier in cortical multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 66, 321-328 (2007).
16. Wegner, C., Esiri, M. M., Chance, S. A., Palace, J. & Matthews, P. M. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 67, 960-967 (2006).
17. Magliozzi, R. et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 68, 477 (2010).
18. Freund, P. et al. Disability, atrophy and cortical reorganization following spinal cord injury. Brain 134, 1610-1622 (2011).
19. Sailer, M. et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 126, 1734-1744 (2003).
20. Narayanan, S. et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann. Neurol. Mar. 41, 385-391 (1997).
21. Varga, A. W. et al. White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J. Neurol. Sci. 282, 28-33 (2009).
22. Dziedzic, T. et al. Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol. 20, 976-985 (2010).
23. Henry, R. G. et al. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J. Neurol. Sci. 282, 61-66 (2009).
24. Audoin, B. et al. Localization of grey matter atrophy in early RRMS: A longitudinal study. J. Neurol. 253, 1495-1501 (2006).
25. De Stefano, N. et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60, 1157-1162 (2003).
26. Furby, J. et al. Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis. Mult. Scler. 15, 687-694 (2009).
27. Sanfilipo, M. P., Benedict, R. H., Sharma, J., Weinstock-Guttman, B. & Bakshi, R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray versus white matter with misclassification correction. Neuroimage 26, 1068-1077 (2005).
28. Roosendaal, S. D. et al. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult. Scler. 17, 1098-1106 (2011).
29. Ceccarelli, A. et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 42, 315-322 (2008).
30. Battaglini, M. et al. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 282, 55-60 (2009).
31. Bendfeldt, K. et al. Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis-a longitudinal voxel-based morphometry study. Neuroimage 45, 60-67 (2009).
32. Pagani, E. et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. Am. J. Neuroradiol. 26, 341-346 (2005).
33. Sepulcre, J. et al. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway. Arch. Neurol. 66, 173-179 (2009).
34. Gilmore, C. P. et al. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J. Neurol. Neurosurg. Psychiatry 80, 182-187 (2009).
35. Kutzelnigg, A. et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 17, 38-44 (2007).
36. Gilmore, C. P. et al. Spinal cord neuronal pathology in multiple sclerosis. Brain Pathol. 19, 642-649 (2009).
37. Howell, O. et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134, 2755-2771 (2011).
38. Lucchinetti, C. F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188-2197 (2011).
39. Calabrese, M. et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch. Neurol. 64, 1416-1422 (2007).
40. Giorgio, A. et al. Cortical lesions in radiologically isolated syndrome. Neurology 77, 1896-1899 (2011).
41. Calabrese, M. & Gallo, P. Magnetic resonance evidence of cortical onset of multiple sclerosis. Mult. Scler. 15, 933-941 (2009).
42. Seewann, A. et al. Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Mult. Scler. 17, 1202-1210 (2011).
43. Chard, D. T. et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 125, 327-337 (2002).
44. Tiberio, M. et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 64, 1001-1007 (2005).
45. Sbardella, E. et al. Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS ONE 8, e63250 (2013).
46. Steenwijk, M. D. et al. What explains gray matter atrophy in long-standing multiple sclerosis? Radiology 272, 832-842 (2014).
47. Calabrese, M. et al. Imaging distribution and frequency of CLs in patients with multiple sclerosis. Neurology 75, 1234-1240 (2010).
48. Vercellino, M. et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J. Neuropathol. Exp. Neurol. 68, 489-502 (2009).
49. Geurts, J. J. et al. Extensive hippocampal demyelination in multiple sclerosis. J. Neuropathol. Exp. Neurol. 66, 819-827 (2007).
50. Cohen-Adad, J. et al. In vivo evidence of disseminated subpial T2∗ signal changes in multiple sclerosis at 7 T: a surface-based analysis. Neuroimage 57, 55-62 (2011).
51. Audoin, B. et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 81, 690-695 (2010).
52. Bendfeldt, K. et al. Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis. Hum. Brain Mapp. 31, 1542-1555 (2010).
53. Bettelli, E. et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 197, 1073-1081 (2003).
54. Krishnamoorthy, G. et al. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nature Med. 15, 626-632 (2009).
55. Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E. & Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14, 164-174 (2004).
56. Ascherio, A. & Munger, K. L. Epstein-Barr virus infection and multiple sclerosis: a review. J. Neuroimmune Pharmacol. 5, 271-277 (2010).
57. Ascherio, A. et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286, 3083-3088 (2001).
58. Levin, L. I. et al. Multiple sclerosis and Epstein-Barr virus. JAMA 289, 1533-1536 (2003).
59. Serafini, B. et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204, 2899-2912 (2007).
60. Serafini, B., Muzio, L., Rosicarelli, B. & Aloisi, F. Radioactive in situ hybridization for Epstein-Barr virus-encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain 136, e233 (2013).
61. Magliozzi, R. et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J. Neuropathol. Exp. Neurol. 72, 29-41 (2013).
62. + T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 9, e1003220 (2013).
63. + T cells. Eur. J. Immunol. 44, 3439-3452 (2014).
64. Sargsyan, S. A. et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 74, 1127-1135 (2010).
65. Willis, S. N. et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 132, 3318-3328 (2009).
66. Lassmann, H., Niedobitek, G., Aloisi, F., Middeldorp, J. M. & NeuroproMiSe EBV Working Group. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 134, 2772-2786 (2011).
67. Aloisi, F., Serafini, B., Magliozzi, R., Howell, O. W. & Reynolds, R. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain 133, e157 (2010).
68. Maggi, F. et al. Low prevalence of TT virus in the cerebrospinal fluid of viremic patients with central nervous system disorders. J. Med. Virol. 65, 418-422 (2001).
69. Sospedra, M. et al. Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog. 1, e41 (2005).
70. Lamberto, I., Gunst, K., Müller, H., Zur Hausen, H. & de Villiers, E. M. Mycovirus-like DNA virus sequences from cattle serum and human brain and serum samples from multiple sclerosis patients. Genome Announc. 2, e00848-14 (2014).
71. Borkosky, S. S., Whitley, C., Kopp-Schneider, A., zur Hausen, H. & de Villiers, E. M. Epstein-Barr virus stimulates torque teno virus replication: a possible relationship to multiple sclerosis. PLoS ONE 7, e32160 (2012).
72. Zeis, T., Graumann, U., Reynolds, R. & Schaeren-Wiemers, N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 131, 288-303 (2008).
73. Baranzini, S. E. et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 133, 2603-2611 (2010).
74. Mastronardi, F. G. & Moscarello, M. A. Molecules affecting myelin stability: a novel hypothesis regarding the pathogenesis of multiple sclerosis. J. Neurosci. Res. 80, 301-308 (2005).
75. Neumann, H., Cavalié, A., Jenne, D. E. & Wekerle, H. Induction of MHC class I genes in neurons. Science 269, 549-552 (1995).
76. Jersild, C. et al. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 2, 1221-1225 (1973).
77. The International Multiple Sclerosis Genetics Consortium (IMSGC) et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214- 219 ( 2011).
78. Martin, R. et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145, 540-548 (1990).
79. Ota, K. et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346, 183-187 (1990).
80. + T cells in multiple sclerosis. J. Immunol. 172, 3893-3904 (2004).
81. Yates, R. L., Esiri, M. M., Palace, J., Mittal, A. & DeLuca, G. C. The influence of HLA-DRB1∗15 on motor cortical pathology in multiple sclerosis. Neuropathol. Appl. Neurobiol. http://dx.doi. org/10.1111/nan.12165 (2014).
82. Höftberger, R. et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 14, 43-50 (2004).
83. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192, 393-404 (2000).
84. Ulvestad, E. et al. HLA class II molecules (HLA-DR,-DP,-DQ) on cells in the human CNS studied in situ and in vitro. Immunology 82, 535-541 (1994).
85. Liblau, R. S., Gonzalez-Dunia, D., Wiendl, H. & Zipp, F. Neurons as targets for T cells in the nervous system. Trends Neurosci. 36, 315-324 (2013).
86. + T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J. Neurosci. 29, 15397-15409 (2009).
87. Suidan, H. S. et al. Granzyme A released upon stimulation of cytotoxic T lymphocytes activates the thrombin receptor on neuronal cells and astrocytes. Proc. Natl Acad. Sci. USA 91, 8112-8116 (1994).
88. + T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. Eur. J. Immunol. 30, 3623-3633 (2000).
89. Aktas, O. et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46, 421-432 (2005).
90. Mizuno, T. et al. Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-γ receptor and AMPA GluR1 receptor. FASEB J. 22, 1797-1806 (2008).
91. + T cell clones use perforin-or Fas/Fas ligand-mediated pathways for target cell lysis. J. Immunol. 158, 2756-2761 (1997).
92. + myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. J. Immunol. 157, 679-688 (1996).
93. + CD4 T cells target oligodendrocytes in multiple sclerosis. J. Immunol. 190, 2510-2518 (2013).
94. Magliozzi, R. et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130, 1089-1104 (2007).
95. Magliozzi, R., Columba-Cabezas, S., Serafini, B. & Aloisi, F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148, 11-23 (2004).
96. Peters, A. et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35, 986-996 (2011).
97. Choi, S. R. et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 135, 2925-2937 (2012).
98. Kramann, N. et al. Increased meningeal T and plasma cell infiltration is associated with early subpial cortical demyelination in common marmosets with experimental autoimmune encephalomyelitis. Brain Pathol. http://dx.doi.org/10.1111/bpa.12180 (2014).
99. Gardner, C. et al. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 136, 3596-3608 (2013).
100. Kooi, E. J., Geurts, J. J., van Horssen, J., Bø, L. & van der Valk, P. Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. J. Neuropathol. Exp. Neurol. 68, 1021-1028 (2009).
101. Guseo, A. & Jellinger, K. The significance of perivascular infiltrations in multiple sclerosis. J. Neurol. 211, 51-60 (1975).
102. Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712 (2005).
103. Reynolds, R. et al. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 122, 155-170 (2011).
104. Fischer, M. T. et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 136, 1799-1815 (2013).
105. Calabrese, M. et al. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann. Neurol. 74, 76-83 (2013).
106. Androdias, G. et al. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann. Neurol. 68, 465-476 (2010).
107. Dutta, R. & Trapp, B. D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68 (Suppl. 3), 22-31 (2007).
108. Kreutzberg, G. W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19, 312-318 (1996).
109. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318 (2005).
110. Aloisi, F. Immune function of microglia. Glia 36, 165-179 (2001).
111. Block, M. L. & Hong, J. S. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem. Soc. Trans. 35, 1127-1132 (2007).
112. Polazzi, E. & Contestabile, A. Reciprocal interactions between microglia and neurons: from survival to neuropathology. Rev. Neurosci. 13, 221-242 (2002).
113. Gray, E., Thomas, T. L., Betmouni, S., Scolding, N. & Love, S. Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques. J. Neuropathol. Exp. Neurol. 67, 888-899 (2008).
114. Vercellino, M. et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J. Neuropathol. Exp. Neurol. 66, 732-739 (2007).
115. Kooi, E. J., Strijbis, E. M., van der Valk, P. & Geurts, J. J. Heterogeneity of cortical lesions in multiple sclerosis: clinical and pathologic implications. Neurology 79, 1369-1376 (2012).
116. Stys, P. K., Zamponi, G. W., van Minnen, J. & Geurts, J. J. Will the real multiple sclerosis please stand up? Nature Rev. Neurosci. 13, 507-514 (2012).
117. Barnett, M. H. & Prineas, J. W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55, 458-468 (2004).
118. Henderson, A. P., Barnett, M. H., Parratt, J. D. & Prineas, J. W. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 66, 739-753 (2009).
119. Lassmann, H., van Horssen, J. & Mahad, D. Progressive multiple sclerosis: pathology and pathogenesis. Nature Rev. Neurol. 8, 647-656 (2012).
120. Fischer, M. T. et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135, 886-899 (2012).
121. Witte, M. E., Geurts, J. J., de Vries, H. E., van der Valk, P. & van Horssen, J. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 10, 411-418 (2010).
122. Campbell, G. R. et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann. Neurol. 69, 481-492 (2011).
123. Nikic, I. et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nature Med. 17, 495-499 (2011).
124. van Horssen, J., Witte, M. E. & Ciccarelli, O. The role of mitochondria in axonal degeneration and tissue repair in MS. Mult. Scler. 18, 1058-1067 (2012).
125. Mahad, D., Ziabreva, I., Lassmann, H. & Turnbull, D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 131, 1722-1735 (2008).
126. Marik, C., Felts, P. A., Bauer, J., Lassmann, H. & Smith, K. J. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130, 2800-2815 (2007).
127. Druzhyna, N. M., Wilson, G. L. & LeDoux, S. P. Mitochondrial DNA repair in aging and disease. Mech. Ageing Dev. 129, 383-390 (2008).
128. Trapp, B. D. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 8, 280-291 (2009).